Tarextumab

Drug Profile

Tarextumab

Alternative Names: Anti-Notch 2/3; Anti-Notch 2/3 monoclonal antibody; OMP-59R5; TRXT

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Notch-2 receptor antagonists; Notch-3 receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 17 Apr 2017 OncoMed Pharmaceuticals completes the phase Ib/II PINNACLE trial in Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (NCT01859741)
  • 17 Apr 2017 Top-line results from the phase Ib/II PINNACLE trial in Small cell lung cancer released by OncoMed Pharmaceuticals
  • 05 Apr 2017 Pharmacodynamics data from the phase Ib/II PINNACLE trial in Small cell lung cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top